Prescient Therapeutics Ltd
ASX:PTX
Prescient Therapeutics Ltd
ASX:PTX
Price:
0.048 AUD
-4%
Market Closed
Updated:
May 2, 2024
Section:
Relative Value
The Relative Value of one
PTX
stock under the Base Case scenario is
0.017
AUD.
Compared to the current market price of 0.048 AUD,
Prescient Therapeutics Ltd
is
Overvalued by 65%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PTX
Relative Value
Base Case
0.017
AUD
Overvaluation 65%
Valuation Multiples
Multiples Across Competitors
PTX Competitors Multiples
Prescient Therapeutics Ltd Competitors
Prescient Therapeutics Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Prescient Therapeutics Ltd
ASX:PTX
|
38.7m AUD | 55.4 | -5 | -2.3 | -2.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
281.3B USD | 5.2 | 58.4 | 12.7 | 19.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
148.1B USD | 5.3 | 22 | 16.4 | 24.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.8B USD | 10.5 | 28.7 | 23 | 24 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
101.7B USD | 7.8 | 25.7 | 17.2 | 18.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133B AUD | 6.1 | 35.1 | 21.3 | 26.4 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 3 | 167.6 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.8B USD | 6.7 | -9.7 | -10.4 | -8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 26.8 | 13.8 | 17.2 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.9T KRW | 17.9 | 72.5 | 44.4 | 61.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
